What is KURA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.94B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KURA?

P/E (TTM) is n/a and 52-week range is $7.36 to $13.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KURA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KURA?

The company profile lists revenue (TTM) near $77M, net income (TTM) near $-29.65B, EPS (TTM) near $-3.36 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Kura Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 88.8M shares outstanding, ISIN US50127T1097 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Kura Oncology Inc

$KURA

Health Care · Biotechnology

IR Run Scenarios

$10.60

+0.76%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 260 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Employees

260

Website

www.kuraoncology.com/

IPO

2015-11-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)